Berenson JR et al. – Bortezomib plus melphalan is a steroid- and immunomodulatory drug-free treatment alternative for relapsed/refractory multiple myeloma (MM) pts who are elderly or with significant comorbidity Methods
Study of safety and efficacy of bortezomib plus melphalan in relapsed/refractory MM
Administration of bortezomib (0.7, 1, or 1.3 mg/m2) on days 1, 4, 8, and 11 and oral melphalan (0.025–0.25 mg/kg) on days 1–4 of a 28-day cycle
Hematologic toxicities defined maximum tolerated dose: bortezomib 1 mg/m2 and melphalan 0.10 mg/kg
Cohorts with higher bortezomib (1.3 mg/m2) and lower melphalan (0.025 and 0.10 mg/kg) doses added due to dose-limiting toxicities of melphalan (more myelosuppressive)
See all
